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Abstract
Background: Recently, provincial health programs in Canada and elsewhere have begun rolling out
vaccination against human papillomavirus for girls aged 9–13. While vaccination is voluntary, the cost of
vaccination is waived, to encourage parents to have their daughters vaccinated. Adult women who are
eligible for the vaccine may still receive it, but at a cost of approximately CAN$400. Given the high efficacy
and immunogenicity of the vaccine, the possibility of eradicating targeted types of the virus may be feasible,
assuming the vaccination programs are undertaken strategically.
Methods: We develop a mathematical model to describe the epidemiology of vaccination against human
papillomavirus, accounting for a widespread childhood vaccination program that may be supplemented by
voluntary adult vaccination. A stability analysis is performed to determine the stability of the disease-free
equilibrium. The critical vaccine efficacy and immunogenicity thresholds are derived, and the minimum
level of adult vaccination required for eradication of targeted types is determined.
Results: We demonstrate that eradication of targeted types is indeed feasible, although the burden of
coverage for a childhood-only vaccination program may be high. However, if a small, but non-negligible,
proportion of eligible adults can be vaccinated, then the possibility of eradication of targeted types
becomes much more favourable. We provide a threshold for eradication in general communities and
illustrate the results with numerical simulations. We also investigate the effects of suboptimal efficacy and
immunogenicity and show that there is a critical efficacy below which eradication of targeted types is not
possible. If eradication is possible, then there is a critical immunogenicity such that even 100% childhood
vaccination will not eradicate the targeted types of the virus and must be supplemented with voluntary
adult vaccination. However, the level of adult vaccination coverage required is modest and may be
achieved simply by removing the cost burden to vaccination.
Conclusion:  We recommend that provincial healthcare programs should pay for voluntary adult
vaccination for women aged 14–26. However, it should be noted that our model results are preliminary,
in that we have made a number of simplifying assumptions, including a lack of age-dependency in sexual
partner rates, a lack of sexual activity outside of the vaccine age-range among females and a uniform age
of sexual debut; thus, further work is desired to enhance the external generalisability of our results.
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Background
Human papillomavirus (HPV) produces epithelial tumors
of the skin and mucous membranes [1]. There are over
100 types, many of which are relatively benign. However,
some types have emerged as high risk because they pro-
duce lesions that may lead to carcinomas [2]. Resulting
disease includes genital warts, respiratory papillomatosis,
and cancer of the cervix, vulva, vagina, anus and the penis
[2], as well as cancers of the head and neck [3]. Prevalence
of HPV in Canada has been estimated at 24% in female
university students [4]. In Ontario, 500 women are diag-
nosed with cervical cancer annually, leading to 140 deaths
[5]. Between 30 and 40 types are transmitted through sex-
ual contact. Without condoms, risk of transmission, given
contact with an infected partner, is close to 90%; this risk
is still high (40%) when condoms are used [6]. No antivi-
rals have been developed for HPV and detection has
largely relied on the recommended yearly pap smear,
which locates cellular abnormalities that indicate that
HPV may be present [7].
Cervical cancer is the second most common cause of
death in women (after breast cancer) and it accounts for
10% of all cancers in women [8]. Progression to malig-
nancy after acquisition of HPV usually takes at least 10
years [8]. Types 16 and 18 account for approximately 70%
of these cervical cancers [8-10]. Merck and GlaxoSmithK-
line (GSK) have developed commercial vaccines which
target types 16 and 18 [8]. Merck's vaccine also protects
against types 6 and 11, which are responsible for 90% of
external genital warts [8]. The combination of a successful
vaccine and vaccination strategy, in combination with the
yearly pap smear, seems to be the best approach towards
preventing cervical cancer. The vaccine has been approved
for women aged 9–26 [11]. Current studies are showing
90–100% efficacy as well as over 98% immunogenicity
rates [8,12] for existing vaccines, with no loss of immunity
for at least 5 years [12]. Current vaccination programs
against HPV [13-19] consider two distinct groups: girls
who have not yet begun to be sexually active and women
under 26 who are sexually active.
Vaccination programs in Canada have begun in several
provinces (Ontario, Nova Scotia, Prince Edward Island) in
Fall 2007, targeting school children aged 9–13 [20]. The
vaccine is covered by Canadian healthcare for girls in this
age group, but is voluntary [5]. Sociological research sug-
gests that about 77% of parents would immunize their
children with the HPV vaccine [21]. Vaccination of
women aged 14–26 is available, but not covered by pro-
vincial healthcare, costing approximately CAN$400 [5]
for a full course (three doses) [8]. State-funded voluntary
HPV vaccination for adults has been underway in other
countries, such as France and Australia, since early 2007
[22]. Possible limitations of a vaccination program
include: i) the vaccine may only be delivered to a propor-
tion p of the population, ii) the vaccine may only confer
immunogenicity in a proportion ε of the vaccinated pop-
ulation (ie the vaccine may not always take when admin-
istered to the patient), iii) the vaccine may have
incomplete efficacy ψ (ie the vaccine doesn't always pro-
tect against infection during sexual intercourse), iv) the
vaccine may wane over time and v) the vaccine does not
target all HPV types.
In this paper, we develop a mathematical model to evalu-
ate the effectiveness of supplementing a childhood vacci-
nation program with voluntary adult vaccination. We
address the following research questions: 1. Can a child-
hood-only vaccination program eradicate targeted types
of HPV? 2. Should an adult vaccination program supple-
ment childhood vaccination? 3. Is eradication of targeted
types possible for vaccines with suboptimal efficacy or
immunogenicity?
Results and Discussion
The mathematical model considers female children who
may be vaccinated or unvaccinated. Female children grow
into sexually active adult women, whereupon unvacci-
nated adult women may become vaccinated, or they may
be infected with HPV. Vaccinated women may still be
infected, although they will have a lower probability of
infection, due to the vaccine. Men are also included in the
model and may be susceptible or infected, but cannot be
vaccinated. See Methods for details. The model is illus-
trated in Figure 1.
There is a threshold of eradication of targeted types given
by
with parameters as given in Table 1. See Methods for
mathematical details. Note that, if the vaccination is not
at all efficacious (ψ  = 0), or if the vaccine confers no
immunogenicity to children (ε = 0), then it is not possible
to eradicate targeted types of the disease, regardless of
how many children or adults are vaccinated.
We chose sample parameters to illustrate this threshold,
using the following key assumptions: females enter the
model as children at age 13, the mean rate of progression
to sexually active adults is 3 years, women are in the sexu-
ally active pool for 10 years (ie until age 26, after which
they cannot be vaccinated, so they are no longer under
consideration), male partners are also in the pool for 10
years, the vaccine may not confer 100% protection and
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the probability of transmission from men to women is
higher than the probability of transmission from women
to men. Although women can still transmit the virus after
age 26, we make the simplifying assumption that they will
only infect male partners who do not continue to find
new, younger female partners. Thus, while 50 year old
men may have sexual relationships with 20 year old
women (and may have multiple partners among this
cohort), we assume that, after age 60, they do not begin
relationships with a new cohort of 20 year old women.
Parameters were also chosen so that the prevalence of
HPV in the sexually active cohort was 24%, in line with
Canadian estimates [4]. The maximum possible vaccina-
tion rate was set so that, if 100% of sexually active adults
were vaccinated with a perfect vaccine, then the average
woman would be vaccinated by 16 years 9 months. See
the Table for parameters used and sample values.
A childhood-only vaccination program can eradicate tar-
geted types of the disease, assuming 95% efficacy of the
vaccine, if 81% of children are vaccinated (Figure 2A).
However, if adult vaccination is included, the burden of
childhood vaccination falls; if 20% of adults are vacci-
nated, then eradication of targeted types could be
achieved with 74% childhood vaccination coverage.
However, if 50% of adults are vaccinated, then eradication
of targeted types could be achieved with only 55% child-
hood vaccination coverage. If no children were to be vac-
cinated, then eradication could still be achieved,
assuming 81% of adults were vaccinated. As efficacy is
reduced, these thresholds increase (Figure 2B). In particu-
lar, for our parameter set, the burden of childhood vacci-
nation coverage without adult vaccination rises to 90%
when the efficacy is reduced to 85%.
If the efficacy is reduced further, then eradication of tar-
geted types is no longer possible (Figure 3A).
The model Figure 1
The model. Schematic representation of the model representing flow of individuals from pre- to post-vaccination. School-
aged girls may be vaccinated (CV) or unvaccinated (CU), depending on the proportion vaccinated (p) and the immunogenicity of 
the vaccine (ε). Children progress to sexually active adults at rate α. Unvaccinated adult women (AU) can either be vaccinated 
(f) or become infected (IU), with probability βN, when they meet an infected man N . Vaccinated adult women (AV) can also 
become infected (IV), but with reduced transmissibility, due to the efficacy of the vaccine ψ. Unvaccinated men (M) become 
infected upon contact with infected women, with transmission probability βM. The mortality rate of children is µC and the leav-
ing rate of adults is µ.BMC Public Health 2008, 8:114 http://www.biomedcentral.com/1471-2458/8/114
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There is a critical vaccine efficacy ψ*, satisfying
such that, if ψ <ψ*, then eradication of targeted types is
not possible. See Methods for details. Thus, even if the
vaccine mounts an immune response 100% of the time
and we can vaccinate 100% of the population, if the effi-
cacy is below this threshold (77% in our example), then
the disease will persist. If the immunogenicity is reduced,
then eradication of targeted types is not possible with a
childhood-only vaccination program (Figure 3B). There is
a critical immunogenicity value, ε*, satisfying
such that, if ε <ε*, then even 100% childhood vaccination
coverage will not eradicate targeted types of the disease. In
this case (assuming ψ > ψ*), there is a critical proportion
of adults who must be vaccinated. In our example, in the
unrealistic case that 100% of children are vaccinated, we
would still require 18% of adults to be vaccinated to
achieve eradication of targeted types if the immunogenic-
ity is reduced to 75% (Figure 3B).
The time course for eradication of targeted types, as with
eradicating any disease, is a long one. We illustrate the
temporal dynamics in Figure 4. Here, we model a commu-
nity where the initial condition is the equilibrium infec-
tion among women in the sexually active cohort we are
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Table 1: List of symbols
Symbol Definition Sample value used Parameter range
CU Unvaccinated female children (state variable)
AU Unvaccinated adult women (state variable)
CV Vaccinated female children (state variable)
AV Vaccinated adult women (state variable)
IU Uninfected adult women (state variable)
IV Infected adult women (state variable)
M Uninfected men (state variable)
N Infected men (state variable)
πW Rate of appearance of new females 50 per year 0–100
πM Rate of appearance of new males 50 per year 0–100
ε Vaccine immunogenicity in female children 98% 75–98%
Vaccine immunogenicity in adult women 98% 75–98%
p Proportion of female children vaccinated 77% 0–100%
Proportion of adult women vaccinated 40% 0–100%
µC Mortality rate of children 1/70 years -1 1/140–1/13
µ Leaving rate of adults 1/10 years-1 1/12–1
α Rate of progression of female children to sexually activity 1/12–1
c Attentuation constant 0.15 years-1 0–0.3
γ Maximal possible rate of adult vaccination 0.1 0–0.2
Rate at which unvaccinated adult women are vaccinated
βN Probability of infection of a woman by an infected man 0.00056 0–0.00112
βM Probability of infection of a man by an infected woman 0.0003 0–0.0006
ψ Vaccine efficacy 95% 85–95%
Sample parameters were chosen so that   (ie the total time between vaccination and leaving was always 13 years), γc-1 = 16.67 (ie the 
optimum age of vaccination for a perfect vaccine with 100% coverage was 16 years 9 months), βN > βM (ie the transmission probability from men to 
women was higher than from women to men), the total prevalence without vaccination was 24% and so that the proportion of adult-only 
vaccination was equal to the proportion of childhood-only vaccination required to eradicate targeted types.
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investigating. (We stress that this number will be much
smaller than the total disease burden in this community.)
To demonstrate the importance of adult vaccination, we
model two scenarios: in the first, 65% of children are vac-
cinated, using a vaccine with 95% efficacy and 98%
immunogenicity, but no adults are vaccinated. In this
case, the number of infections is reduced by about half
(Figure 4A), but is not eradicated after more than a cen-
tury. However, if the same vaccination program is admin-
istered, but, additionally, 40% of adults are vaccinated,
then the number of infections approaches zero (Figure
4B).
The dependence of the results on parameter variation was
also determined. While equation (3) is independent of
the sample parameters we chose, and thus is effectively a
robust sensitivity analysis unto itself, we illustrate the var-
iation among likely parameter ranges, as given in the
Table. The results are illustrated in Figure 5. We use the
output variable as the proportion of adults who must be
vaccinated in order to achieve eradication of targeted
types, assuming that 77% of children are vaccinated [21].
If women spend less time sexually active, then the thresh-
old may be reduced to zero (Figure 5A). Conversely, if
women spend more time sexually active, then the thresh-
old may rise considerably, although it will not exceed
100%, even if girls become sexually active as early as 13,
which we argue is unlikely for the Canadian average. If the
optimal age of vaccination with perfect coverage, γ/c,
increases, then the threshold increases slightly (Figure
5B), but there is little variation even if a perfect vaccine
can reach all "adult" women by age 13. Since parameters
βN, βM, πM and πW always appear together in (3), we can
consider them as a single unit. Even if the transmission
probabilities or birth rates collectively double, then the
threshold will only increase to 65% required adult vacci-
nation (Figure 5C). Finally, there is little dependence on
childhood mortality, as expected (Figure 5D); if life
expectancy is significantly shorter than 70 years, then the
threshold will be reduced, but we do not expect much var-
iation in this parameter, given overall Canadian life
expectancies.
Conclusion
Despite human papillomavirus being one of the most
prevalent sexually transmitted infectious diseases [23],
eradication of targeted types is not only possible, but is
feasible, under existing vaccination programs, if adults are
included. While eradication of targeted types using a
childhood-only vaccination program is possible for vac-
cines with currently estimated efficacy (90–99%) and
immunogenicity (98%), it nevertheless poses an
extremely high burden of coverage that must be met if
only children are to be vaccinated. Crucially, sociological
surveys of parents indicated that only 77% were willing to
immunise their children with the vaccine [21]. Even in the
best-case scenario of a vaccine with 95% efficacy and 98%
immunogenicity, our results demonstrate that this pro-
portion of children vaccinated is insufficient for eradica-
tion unless a small, but nontrivial, proportion of adults
(approximately 16%) is also vaccinated (Figure 2A).
While vaccinating children is desirable, given that the
majority of children can be located via the school system,
our model demonstrates that any such vaccination pro-
gram should be supplemented by an adult vaccination
program. A widespread adult vaccination program may be
unfeasible; however, our results indicate that eradication
of targeted types is possible if the proportion of vaccinated
children is large, while the proportion of vaccinated
adults is modest. Since we do not need to locate all, or
even most, sexually active young adults, the required cov-
erage may be achieved merely by not posing obstacles to
voluntary adult vaccination. Consequently, we recom-
mend that adult vaccination in Canada be paid for by pro-
vincial healthcare, just as both childhood and adult
vaccination of Hepatitis B currently is.
By determining an eradication threshold (see Methods),
our model can also be used to examine scenarios outside
the range of currently available data. Specifically, we
investigated the effects that suboptimal efficacy or immu-
nogenicity of the vaccine may have. Although these values
have been high in the literature, such data have been
taken from clinical trials, which have a relatively small
sample size. With a vaccination program targeting a signif-
icant number of children, we allowed for the possibility
that these effects may not be as high in the broader popu-
lation. We demonstrated that there is a critical vaccine effi-
cacy, below which eradication of targeted types is not
possible, regardless of how many people are vaccinated.
We also showed that there is a critical vaccine immuno-
genicity, below which even 100% childhood vaccination
coverage will not lead to eradication of targeted types.
Thus, a small but nonzero proportion of adult vaccination
coverage is crucial for eradication of targeted types in this
case.
A number of cohort, dynamic and population models
have been developed in the literature, most of which show
that vaccinating women can be cost-effective [24]. Most
mathematical models have consistently predicted a useful
role for vaccination, although assumptions about natu-
rally acquired immunity and heterogeneity in risk behav-
iours have varied [26]. One such model, developed before
the vaccine was made available, predicted a 30% reduc-
tion in epidemic prevalence if females were vaccinated
[25]. However, this model assumed the vaccine would
only be 75% effective, in line with our conclusions. The
annual proportion of cervical cancer cases prevented wasBMC Public Health 2008, 8:114 http://www.biomedcentral.com/1471-2458/8/114
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shown to be much higher when early adolescents were tar-
geted, in a modelling study based on vaccination in Fin-
land [27]. The authors recommended the implementation
of catch-up vaccination at the start of a vaccination pro-
gramme (ie vaccinating outside the target age group) in
order to increase the speed with which a decrease in HPV
and cervical cancer incidence is observed. Vaccinating girls
and women in a catch-up program in the United States
was estimated to be cost-effective, relative to other com-
monly accepted healthcare programs [28].
Our model has several limitations, which should be
noted. First, we assume that the vaccine does not wane.
Although this is consistent with current understandings of
the vaccine, we only have five years of data to rely on. We
assume that men who have sexual relations with women
in the sexually active cohort (ie women who are eligible
for adult vaccination) do not continue to find new part-
ners in this age group as time goes on. Thus, while 50 year
old men may sometimes have sexual relations with (mul-
tiple) 25 year old women, we assume that those same men
stop having sexual relations with new 25 year olds after a
certain period of time. In this way, the sexually active
cohorts of men and women are linked only for the time
(approximately 10 years) that adult women are sexually
active and eligible for vaccination. We also assume that
the vaccine plays no role in modifying the nature of the
disease for infected vaccinated women; consequently, we
assume that men infected by vaccinated women have the
same probability of infection as men infected by unvacci-
nated women. However, we argue that if this were not the
case, then the overall burden of infection would only be
lowered, so our results are conservative.
It should also be noted that achieving actual eradication
of targeted strains may be difficult in practice. Our model
does not include stochasticity, although stochastic effects
tend to hasten eradication. Furthermore, our model does
not include age structure, which can influence prediction
significantly, since sexual-mixing patterns tend to be
highly age-dependent and heterogeneity will likely slow
down transmission dynamics relative to homogenous
mixing. The model also does not include type structure;
this will have important consequences for replacement
effects, ecological effects and other kinds of type interac-
tion. Even eradicating types 16 and 18 may prove difficult
within the context of high Canadian vaccine coverage;
reintroductions from other populations with lower vac-
cine coverage, or vaccination heterogeneity among Cana-
dian communities (eg rural or indigenous populations)
may result in a recurring low epidemic. Such a situation
currently exists with Hepatitis A, which has high vaccina-
tion coverage in Canada, but reintroductions occur from
the United States [29]. Nevertheless, reducing the preva-
Thresholds of eradication Figure 2
Thresholds of eradication. Thresholds of eradication of 
targeted types for vaccination coverage levels in children ver-
sus adults. A. Threshold curve assuming 95% efficacy. Param-
eters are given in the Table. If no adult vaccination is 
undertaken, then a childhood vaccination program must 
cover 81% of the school-aged population for eradication of 
targeted types. If 20% of adults are vaccinated, then the bur-
den of childhood vaccination reduces to 74%. However, if 
50% of adults are vaccinated, then eradication of targeted 
types can be achieved with only 55% of children vaccinated. 
B. If the efficacy of the vaccine is reduced to 85%, the eradi-
cation threshold is increased, assuming all other parameters 
remain the same.
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lence to the lowest levels possible, as predicted by our
results, would obviously be the most desirable outcome.
A small proportion of adult vaccination can have a signif-
icant impact on eradication of targeted HPV types, when
supplementing a large childhood vaccination program.
This is due to the fact that childhood vaccination is a
binary choice (children are either vaccinated or they are
not), whereas adult vaccination is a rate, so that unvacci-
nated adults have a continual chance of being vaccinated,
during their years in the sexually active cohort, if they are
not infected first. However, there are drawbacks to adult
vaccination: administering a vaccine to adults requires
expensive physician office visits and compliance rates may
be low. School-based vaccination is the cheapest and
most efficient form of vaccination in the conventional
sense of the term.
The mathematical model is a general one, with results that
extend (via specific choice of parameters) to a variety of
communities. We focus on Canada for specific implemen-
tation recommendations, but the model is applicable to
other communities. It should also be noted that it may
take decades, even centuries, to eradicate targeted types of
the disease (Figure 4), but the most significant reduction
should happen within 50 years. This is a remarkably fast
timescale for disease eradication [30], but is possible
because of the high efficacy and immunogenicity of the
vaccine. However, even if eradication of targeted types is
not achieved, vaccination of both children and adults is
clearly desirable and efforts should still be made to vacci-
nate as widely as possible.
Future work will involve examining the differences
between the Merck and GSK vaccines, the possibility of
vaccines that wane and targeted vaccination for adults. A
targeted vaccination program for adults could be imple-
mented by offering free vaccination at STD clinics. This
allows targeting of the subpopulation responsible for
transmitting most sexually transmitted infections,
although it should be noted that such a subpopulation is
likely to already have high HPV incidence before attend-
ing the clinic. Such a model of targeted vaccination would
require separate consideration for high-risk individuals.
We will also generalise the model to include factors such
as age-dependency in sexual partner rates, sexual activity
outside of the vaccine age range among females and vari-
able ages of sexual debut.
Methods
The model
The mathematical model that we have developed
accounts for the vaccination of female children (C) and
adult women (A). In particular, we assume that the pool
of sexually active adults only includes women in an age
Suboptimal efficacy and immunogenicity Figure 3
Suboptimal efficacy and immunogenicity. Suboptimal 
values of the efficacy or the immunogenicity lead to qualita-
tive changes in the outcome. A. There is a critical vaccine 
efficacy (77% in this example), such that no amount of vacci-
nation can eradicate targeted types of the disease if the effi-
cacy falls below this critical value. In this case, eradication of 
targeted types could only occur if more than 100% of chil-
dren were vaccinated, which is not possible. B. If the vaccine 
efficacy allows for eradication of targeted types, there is a 
critical vaccine immunogenicity (80% in this example), such 
that even 100% of childhood vaccination will not eradicate 
targeted types of the disease. In this case, there is a minimum 
level of adult vaccination coverage that is required for eradi-
cation of targeted types (18% if the immunogenicity falls to 
75%), even if 100% childhood coverage levels can be 
achieved. Adult immunogenicity was assumed to be equal to 
childhood immunogenicity. All other parameters as in the 
Table.
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range where they can still be vaccinated, as well as their
male partners. Since men are not being vaccinated, we
include them in our model only as age-equivalent cohort
sexual partners of adult women. Thus, we account for the
situation where older infected males may infect younger
females who have or have not been vaccinated and who in
turn infect other males. However, we assume that any
men who interact with women in this cohort only do so
for a finite amount of time (eg 10 years), although they
may have multiple partners among this age group during
that time. That is, while these men may have multiple
partners among women aged 16–26, after a while they
exhaust their contacts in this age group and are thus
removed from the model.
We assume all vaccinated individuals are vaccinated
before infection. Adult females vaccinated after infection
are classified as "infected", since we assume that vaccina-
tion has no effect on this group. We consider vaccinated
female children (CV) and female adults (AV) as those who
received the vaccine and for whom the vaccine conferred
immunogenicity. All other female individuals are func-
tionally unvaccinated (CU, AU).
We treat men as either uninfected (M) or infected (N)
with infection probability βM after interaction with an
infected woman. Infection of an unvaccinated woman
(AU) via contact with an infected man (N) occurs with
transmission probability βN and results in an infected
unvaccinated woman (IU). We assume that the vaccine
confers no disease-modifying effects once infection has
occurred; thus, we assume that the probability of infection
is the same for men, regardless of whether their (infected)
partners are vaccinated or unvaccinated. We also assume
that the vaccine does not wane over time.
If the vaccine efficacy is not perfect, then vaccinated indi-
viduals have the potential to become infected. Infection of
a vaccinated woman (AV) via contact with an infected man
occurs with transmission probability βN, mediated by the
efficacy (ψ) of the vaccine (βN (1 - ψ)), resulting in an
infected vaccinated woman (IV). Thus, if the vaccine is
100% effective, transmission will be zero. Conversely, if
the vaccine is completely ineffective, transmission is iden-
tical to the probability of infection for unvaccinated indi-
viduals, βN.
The rate of appearance of new females is πW while that of
males is πM. The mortality rate of children is µC and the
leaving rate of adults (including mortality) is µ. In this
model, we do not consider disease-induced mortality,
since it does not play a role in removing individuals from
the sexually active pool that we are considering [8,31].
Female children progress to adulthood at a rate α. Unvac-
cinated adult females who were not vaccinated as children
may be vaccinated as adults via a function f denoting the
rate at which unvaccinated adult females are vaccinated.
This function depends on the proportion of adults vacci-
nated   and the immunogenicity of the vaccine in adults
:
p
ε
Timecourse of eradication Figure 4
Timecourse of eradication. Time course dynamics among 
a community where initial conditions are taken to be the 
equilibrium values of an existing infection, for a vaccine with 
95% efficacy and 98% immunogenicity. A. If 65% of children 
are vaccinated, but no adult vaccination occurs, the preva-
lence in the sexually active cohort is reduced to approxi-
mately half of the previous disease burden after 150 years 
and remains so thereafter. B. If 65% of children and 40% of 
adults are vaccinated, the number of infections in the sexually 
active cohort continues to decline, eventually approaching 
zero. All other parameters as in Figure 4A.
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Dependence on parameter variation Figure 5
Dependence on parameter variation. Sensitivity of eradication threshold on parameter variation, assuming 77% childhood 
vaccination. A. If the average length of sexual activity before age 26 is 9 and a half years or less, then no adults need be vacci-
nated. If this time increases, then the threshold also increases, but still remains below 100%, even if children begin sexual activ-
ity at age 13. B. Variation as the optimal age of vaccination varies. This rate measures the age at which adult women are 
vaccinated, assuming 100% of adults are vaccinated with a perfect vaccine. In this case, there is little variation in the output. C. 
Variation in the transmission probabilities and birth rates. These parameters are always linked, so we examine them as a single 
unit. Even if these parameters collectively double, eradication could still be achieved with 65% adult vaccination. D. Variation in 
the childhood mortality rate. The output is relatively steady, unless mortality is very high. In this (unlikely) scenario, life expect-
ancy of 30 years (17 years after vaccination at age 13) or less would clearly obviate the need for an adult vaccination program.
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with c an attenuation constant and cγ-1 the maximum pos-
sible rate of vaccination, assuming perfect coverage and
immunogenicity. The proportion of adult vaccinations is
thus .  Since  f corresponds to the rate of vaccination of
adults (ie the rate at which unvaccinated adults leave the
unvaccinated pool to go to the vaccinated pool), we want
the rate to be zero if no adults are being vaccinated and we
want the rate to be high if all adults are vaccinated (ie
adults are vaccinated immediately upon entering). The
model is illustrated in Figure 1.
Mathematical analysis
Mathematically, our model is represented as follows:
with the function f given by (2).
The disease-free equilibrium satisfies
and  . We assume  . All
other parameters are assumed to be positive. At the dis-
ease-free equilibrium, the Jacobian matrix is
Then det (J - λI) = (- µC - α - λ)2 (- µ - λ)2(- f - µ - λ) det M,
where
Thus, the largest eigenvalue for J will be the largest eigen-
value for M and so we can reduce the problem to solving
λ3 + αλ2 + βλ + γ = 0
where
α = 3µ
β = 3µ2 - (1 - ψ)βMβNMAV + βNAUβMM
γ = µ3 - (1 - ψ) µβMβNMAV + µβNAUβMM.
By the Routh-Hurwitz condition, all roots will have nega-
tive real parts if α > 0, γ > 0, and αβ - γ > 0. Clearly α > 0.
We can write the third condition as
αβ - γ = 6µ3 + 2γ,
which will be positive if γ > 0. Thus, all roots will have
negative real part if
µ2 - βNβMM[AU + (1 - ψ)AV] > 0.
Solving for εp in terms of   and substituting equilib-
rium values, our eradication threshold is thus
with
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Differentiating (3), we have
It follows that there is a critical vaccine efficacy ψ*, satis-
fying
such that if ψ <ψ*, then eradication of targeted types is not
possible. Thus, even if the vaccine mounts an immune
response 100% of the time and we can vaccinate 100% of
the population, if the efficacy is below this threshold, then
the disease will persist. See Figure 3A.
By setting p = 1 and   = 0, it also follows from (3) that
there is a critical immunogenicity value ε*, satisfying
such that if ε <ε*, then even 100% childhood vaccination
coverage will not eradicate targeted types of the disease.
From (3), when p = 1, we have
Define
For ψ > ψ*, and ε <ε*, θ > 0. It follows that the minimum
level of adult vaccination required for eradication of tar-
geted types,   satisfies
Since θ > 0, it follows that   > 0. If the immunogenicities
ε and   are not too small, then   < 1 (since γ is small).
Note that we are not assuming that childhood immuno-
genicity is necessarily the same as adult immunogenicity.
Thus, if childhood immunogenicity is below ε* (but not
so small that the vaccine is nonfunctional), then there is a
minimum level of adult vaccination coverage that must be
achieved for eradication of targeted types. See Figure 3B.
To examine sensitivity of results on parameter variation,
we used the output parameter as the proportion of adults
who should be vaccinated in order to eradicate targeted
types. Thus, rearranging equation (3), we have
where
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